Every atomic assertion extracted from the underlying record, ranked by evidence strength.
If approved, lonvo-z would be the world's first gene-editing therapy delivered in-vivo (inside the body).
AI is amplifying, not cannibalizing, the legacy cloud business.
Robinhood Gold is designed to transform intermittent brokerage users into high-frequency financial users.
Robinhood is shifting from a transactional model to a recurring revenue, relationship-driven model.
The hyperscalers' capital expenditure (capex) is racing to keep pace with contracted demand, not chasing a hypothetical future.
Cloud growth is accelerating, not maturing, driven by strong AI adoption.
Major equity index providers are overhauling their inclusion rules in anticipation of a potentially largest IPO wave in history.
Gold subscriptions have been generating approximately $100 million in annualized recurring revenue (ARR).
Robinhood Gold is following a playbook similar to Amazon Prime, priced to maximize adoption instead of near-term revenue.
Gold users adopt retirement accounts at 3.3-times the rate of non-Gold users.
Robinhood's products are reinforcing one another: Banking drives deposits, deposits fund investing, and spending data informs credit.
On average, HAE patients experience two or more attacks per month, each lasting several days if untreated.
HAE patients on modern prophylactics face lifelong chronic treatment that does not fully protect against occasional attacks.
The Gold Card is generating annualized recurring revenue not far behind Gold subscriptions.
Robinhood Strategies hit $1.5 billion in assets under management (AUM) in little more than a year.
The Gold Card has quadrupled to 765,000 users over the past year.
Approximately 40% of new Robinhood users opt into Gold at signup.
During the six-month efficacy evaluation period, lonvo-z patients experienced 87% fewer attacks than placebo patients.
Lonvo-z could pave the way for one-time treatments to reach a much broader range of diseases.
HAE is a rare genetic disease impacting approximately 7,000 patients in the US.
HAE patients are diagnosed at an average age of 20 years.
HAE leads to the overproduction of bradykinin, an inflammatory molecule.
Bradykinin triggers sudden, painful swelling attacks in the face, abdomen, extremities, and airway.
HAE attacks can be life-threatening when they impact the throat.
By the end of 2025, approximately 90% of eligible US Casgevy patients enjoyed reimbursed access.
Modern prophylactic HAE therapies reduce attack rates by approximately 70-90% in Phase 3 trials.
ARK's research estimates a real-world price of $3 million per HAE patient for lonvo-z.
Casgevy was the first CRISPR-based gene-editing therapy to reach the market.
Casgevy treats sickle cell disease.
Casgevy uses ex-vivo gene editing, where cells are edited outside the body.
The lonvo-z readout is a landmark for gene-editing.
Robinhood Banking accumulated $1.6 billion in deposits in the first quarter, two quarters after rolling out.
Inactivating KLKB1 interrupts the production of bradykinin, preventing HAE swelling attacks.
Lonvo-z's editing tools inactivate KLKB1 in the liver, the gene that produces kallikrein.
Patients receive the lonvo-z infusion in an outpatient setting over two to four hours.
Intellia's Phase 3 trial randomly assigned 80 HAE patients in a 2:1 ratio to receive either lonvo-z or a placebo.
Lonvo-z is a one-time gene-editing therapy for hereditary angioedema (HAE).
100% of lonvo-z patients benefited from some reduction in attack rate relative to baseline.
62% of lonvo-z patients experienced no attacks at all.
The lonvo-z trial results met its endpoints with high statistical significance.
The trial used a crossover design, with placebo patients receiving lonvo-z after a six-month observation period.
Mean attack rates in both the original treatment arm and the placebo crossover arm fell rapidly to nearly zero within 8 weeks of crossover dosing.
Every patient who received lonvo-z benefited from the near-elimination of attacks.
Lonvo-z had a favorable safety profile with no serious liver safety signals.
One critique of lonvo-z is its permanence, questioning why to choose an irreversible gene edit over effective prophylactics.
Intellia's survey data show 68% of HAE patients are highly concerned about the need for lifetime medication.
Intellia's survey data show 80% of HAE patients are concerned about shifts in health insurance coverage inhibiting therapy access.
A one-time treatment like lonvo-z would eliminate concerns about lifetime medication and insurance coverage shifts.
A second critique suggests the lonvo-z edit might not be permanent enough due to limited long-term durability data.
Critiques about permanence and durability echoed those Casgevy navigated after its approval.
Lonvo-z uses in-vivo gene editing, where editing components are delivered through one intravenous infusion.
The number of patients receiving Casgevy infusions jumped from 5 in 2024 to 64 during 2025.
The US wholesale acquisition cost for Casgevy is $2.2 million per dose.
Commercial uptake for gene-editing therapies is accelerating even at premium pricing.
The Casgevy treatment journey can take up to 12 months to complete, involving stem-cell collection, chemotherapy, infusion, and recovery.
ARK's modeled value-based price for lonvo-z is approximately $11 million per HAE patient.
A one-time gene-editing therapy for every HAE patient today could save the healthcare system approximately $52 billion in direct costs over the remaining lives of the ~7,000 US patients.
Cost savings create a clear incentive for payers to reimburse a one-time treatment over costly lifelong prophylactic care.
The Institute for Clinical and Economic Review (ICER) concluded that lifelong prophylactic HAE care is priced above the value delivered.
Intellia Therapeutics reported positive topline Phase 3 results for lonvoguran ziclumeran (lonvo-z) last week.